PMLive1d
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...
Rheumatology Advisor4d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...